(Yicai) Oct. 27 -- Some of the strongest performers among the 208 companies listed on Shanghai's Star Market that have revealed their third-quarter earnings or outlooks are new energy and biopharmaceutical firms.

More than half of the over 200 firms listed on the Nasdaq-style mainland board for innovative companies report or predict rising gains for the three quarters.

The Star Market was home to nearly 550 listed companies when it celebrated its fourth anniversary in July and their market caps tallied around CNY6.6 trillion (USD901.8 billion).

Going forward, renewables are a good pick as the average net profit growth among the seven photovoltaic firms that have announced their performance for the first three quarters is CNY2.2 billion (USD306.3 million), more than doubled from a year ago, due to robust market demand. 

Some of the outliers are two solar panel makers Jinko Solar and Trina Solar. Jinko is expected to have boosted its net profit to CNY6.5 billion, up by almost four times. Trina predicts a 90 percent addition to reach CNY5.6 billion.

The fortunes are spilling over to suppliers. From January to September, Gaoce Technology, a supplier of cutting tools, widened its revenue by 92 percent to CNY4.2 billion while its net profit almost tripled to CNY1.2 billion, caused by an increase in orders of PV equipment.

Moreover, Jinpan Smart Technology, a manufacturer of power transmission equipment, reported a 98 percent increase in gains to CNY333 million (USD45.5 million) during the first nine months while revenue rose by 50 percent to CNY4.8 billion.

Winners in the biopharma field include Sunshine Guojian Pharmaceutical, an antibody-drug developer, which reported a 138-fold increase in net profit in the first three quarters to CNY164 million. 

Moreover, Allist Pharmaceuticals, a Shanghai-based developer of cancer treatments, earned CNY397 million in net profit, or over six times as much as it did a year ago while its operating income almost tripled to CNY1.3 billion because its Fuzheng Meitinib tablets were included in the national medical insurance program.

Among medical device makers, SWS Hemodialysis Care, a supplier of blood purification solutions, stood out with a nearly threefold net profit boost to CNY47 million (USD6.4 million). Meanwhile, its operating income surged by 71 percent to CNY181 million.

Editor: Emmi Laine